Researchers Found That Use of Patient SafetyNet
with Masimo SET® Pulse Oximetry and Acoustic Repsiratory Rate
(RRa®) Monitoring Reduced Nursing Workload Related to Postoperative
Respiratory Assessment by More Than 60%
Masimo (NASDAQ: MASI) announced today the findings of a study
published in the Journal of PeriAnesthesia Nursing in which Drs.
Mashasi Ishikawa and Atsuhiro Sakamoto at Nippon Medical School in
Tokyo evaluated the utility and impact of Masimo Patient SafetyNet™
by surveying nurses before and after implementation.1 The
researchers found that use of the remote monitoring and clinical
notification system decreased the number of physical assessments
needed, resulting in a reduction in the nursing workload, and also
recommended the use of continuous respiratory rate and oxygen
saturation monitoring (which was implemented as part of the system)
after general anesthesia for patients’ safety.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210516005044/en/
Masimo Patient SafetyNet™ (Graphic:
Business Wire)
Noting the importance of frequent postoperative respiratory
assessment, especially for patients on opioids, the researchers
hypothesized that use of Patient SafetyNet, which displays near
real-time information from connected bedside patient monitors at
central/remote surveillance stations, could facilitate such
evaluations “without major patient complications.” To study the
effects of adopting such a solution, they implemented Masimo
Hospital Automation™ with Patient SafetyNet and Masimo Radical-7®
Pulse CO-Oximeters® at the bedside, on all general floors. After
implementation, patients’ oxygen saturation (SpO2) and acoustic
respiration rate (RRa®) were continuously monitored at the bedside,
with the data relayed to the central Patient SafetyNet View
Stations. Remote alarm notifications were programmed for the
following conditions: SpO2: < 90% for > 10 seconds;
bradypnea: < 8 breaths/minute for > 2 minutes; tachypnea:
> 30 breaths/minute for > 2 minutes. When any of these
physiological limits was violated, nurses performed a manual
respiratory check (which typically involved use of a stethoscope
and a pulse oximeter).
To measure the impact of the Patient SafetyNet system with
continuous acoustic respiration rate monitoring, the researchers
surveyed 75 nurses 3 months before and 1 month after
implementation, asking about a variety of methods and problems
related to postoperative respiratory monitoring before/after use of
the system; the usefulness of a central/remote monitoring system;
and the effects of Patient SafetyNet on their workload. Among other
results, the percentage of nurses who found central remote
monitoring to be useful increased from 78.7% pre-implementation to
89.3% post-implementation, and the percentage who found continuous
monitoring useful increased from 88.0% to 98.7%. 96% of nurses
reported that they were able to attend patient bedsides within one
minute of alarm occurrence. Problems recorded in the surveys
included false alarms related to tachypnea, triggered by the
patient’s speaking, and a tendency to avoid early ambulation
because of being continuous monitored.
In addition, the researchers collected retrospective data from
patient records about the number of postoperative respiratory
checks each patient received for 3 months before and 3 months after
system implementation. They found that the average frequency of
clinical examination was reduced from 11.0 ± 2.3 to 5.1 ± 1.3,
representing a reduction of 61.3% in nursing workload related to
postoperative respiratory assessment.
The researchers concluded, “The merits of the Patient SafetyNet
system were that it could be useful for early detection when the
respiratory condition gets worse and evaluation of the causes for
deterioration of respiratory status using numerical values and
waveforms. Therefore, the Patient SafetyNet system is suitable for
cases requiring continuous sedative or opioid infusions, with poor
general condition or depressed levels of consciousness. Continuous
monitoring of respiratory rate and SpO2 after general anesthesia is
recommended for patients' safety. Moreover, the Patient SafetyNet
system can decrease the number of respiratory assessments of
postoperative patients in the general wards, resulting in reduction
of nurse’s workload.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes, reduce the
cost of care, and take noninvasive monitoring to new sites and
applications. Masimo SET® Measure-through Motion and Low Perfusion™
pulse oximetry, introduced in 1995, has been shown in over 100
independent and objective studies to outperform other pulse
oximetry technologies.2 Masimo SET® has also been shown to help
clinicians reduce severe retinopathy of prematurity in neonates,3
improve CCHD screening in newborns,4 and, when used for continuous
monitoring with Masimo Patient SafetyNet™ in post-surgical wards,
reduce rapid response team activations, ICU transfers, and
costs.5-8 Masimo SET® is estimated to be used on more than 200
million patients in leading hospitals and other healthcare settings
around the world,9 and is the primary pulse oximetry at 9 of the
top 10 hospitals according to the 2020-21 U.S. News and World
Report Best Hospitals Honor Roll.10 Masimo continues to refine SET®
and in 2018, announced that SpO2 accuracy on RD SET® sensors during
conditions of motion has been significantly improved, providing
clinicians with even greater confidence that the SpO2 values they
rely on accurately reflect a patient’s physiological status. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67®, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris® Gateway,
iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView
:60™, and Masimo SafetyNet™. Additional information about Masimo
and its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Ishikawa M, Sakamoto A. Patient SafetyNet for the Evaluation of
Postoperative Respiratory Status by Nurses: A Presurvey and
Postsurvey Study. J PeriAnesth Nursing. DOI:
https://doi.org/10.1016/j.jopan.2020.03.005.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Patient SafetyNet™,
Radical-7®, SET®, and RRa®. These forward-looking statements are
based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, Radical-7, SET®,
and RRa, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to COVID-19; as well as other factors
discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210516005044/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024